Galectin Therapeutics reported $27.65M in Assets for its fiscal quarter ending in June of 2024.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Galectin Therapeutics USD 27.65M 1.76M Jun/2024
Gilead Sciences USD 49.36B 6.92B Jun/2026
Immunic USD 189.74M 165.69M Mar/2026
Incyte USD 7.87B 533.53M Jun/2026
Merck USD 128.68B 8.18B Mar/2026